The study, published July 8 in the journal Clinical Infectious Diseases, leveraged the high degree of technical and data standardization of Northwell Health Laboratories to analyze 46,793 patients who were tested for the virus between March 4 and April 10, 2020. Of those tested, 26,735 or 57.1% of patients revealed a positive diagnosis.
About 30% of those who tested positive for COVID-19 (8,174 people) were hospitalized.
This study provides further evidence that COVID-19 infection was widespread across the greater New York metropolitan area at the time that diagnostic testing became available in early March, and provides detailed demographic and geographic information about persons who were tested during the first five weeks of the outbreak.
The highest positive cases were noted in Queens County (68.5 % of persons tested), Kings County (62.3%), and Bronx County (59.2%). The lowest positive rates were noted for Westchester County (46.4%) and Suffolk County (51.2%).
Dr. Crawford and his team found that males were more likely to be positive for COVID-19 than females, and test positivity rates increased progressively with age.
For both males and females age 25 and under, the estimated regional case incidence by April 10 was well below 1%.
For females age 25 and above, the estimated regional case incidence rose steadily from 1.7% to 2.6% through age 84 and was 4.7% for age 85 and above. For males age 25 and above, estimated regional case incidence rose from 1.6 % at age 25 to 4.4% through age 84 and was 6.0% for age 85 and above.
Northwell's service area includes some of the most diverse neighborhoods in the world. In regard to race, the Black population (both sexes) registered a positivity rate of 67.8% compared with the Asian population (62.3%) and White population (55.5%).
Information was not available for test positivity rates in the Hispanic population. The highest test positivity rates were among Black males (72.1%) and Asian males (71.6%).
The majority of hospital admissions for COVID-19 (7,292 persons) were immediately upon presentation of a symptomatic patient to a hospital emergency room.
However, a small number of persons who tested positive for COVID-19 as outpatients were subsequently admitted to the hospital (882 persons), a median of five days after their test had been performed.
This research was done in collaboration between the Feinstein Institutes and Cold Spring Harbor Laboratory (CSHL), with key insights from Partha Mitra, PhD, professor at CSHL.
The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.
Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes includes institutes of behavioural science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA